

**DEPARTMENT OF DEFENSE
PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS
INTERIM MEETING**

Addendum March 20, 2017

BASIC CORE FORMULARY (BCF) CLARIFICATION

A. Proton Pump Inhibitors (PPIs)—Esomeprazole (Nexium)


Following the February 2017 DoD P&T Committee meeting, the Pharmacy Operations Division became aware of a contract cancellation that would significantly impact Military Health System expenditures for the PPI Drug Class. An interim meeting was held on March 7, 2017, to determine the clinical and cost-effectiveness, and Uniform Formulary (UF) status of the PPIs.

The PPIs were last reviewed for UF Placement in May 2007. At that time, omeprazole (Prilosec generic) and esomeprazole (Nexium) were designated as BCF and step-preferred, with the remainder of the PPIs designated as nonformulary and non step-preferred. Since that time, several cost-effective generic formulations have entered the market, and pantoprazole and rabeprazole have been designated with UF and step-preferred status. The branded esomeprazole (Nexium) product is exponentially more expensive than therapeutically equivalent generic PPIs. Generic formulations of esomeprazole are available, but are not Trade Agreements Act (TAA) compliant.

1. **COMMITTEE ACTION: ESOMEPRAZOLE (NEXIUM) REMOVAL FROM THE BCF**—The P&T Committee recommended (14 for, 0 opposed, 0 abstained, 3 absent) the following for the PPIs, to be implemented upon signing:

- Remove esomeprazole (Nexium) from the BCF,
- Maintain omeprazole (Prilosec generics) on the BCF; note that this excludes 40 mg Prilosec capsules; and,
- Add pantoprazole (Protonix generics) to the BCF.

SUBMITTED BY



John P. Kugler, M.D., MPH
DoD P&T Committee Chair

DECISION ON RECOMMENDATIONS



RADM Colin Chinn, MC, USN
Acting Deputy Director, DHA
for R.C. Bono, VADM, MC, USN,
Director, DHA